Auxly Cannabis Group Inc.

TSX:XLY.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$3.53 +0.00%

+$0.00 today

Market cap
$364.42M
Beta
1.16
P/E (TTM)
7.3
EPS (TTM)
$0.02
52W Low $0.08High $0.19

Volume 0.13M

Average 0.71M

XLY.TO EBITDA Margin

EBITDA as a percentage of revenue.

Auxly Cannabis Group Inc.TSX: XLY.TO

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to 19.0%

EBITDA Margin was 19.0% in Q1 FY2026, down 7.7 pp from a year earlier. On a trailing-twelve-month basis it was 31.0%, up 5.0 pp year over year. Over 3 fiscal years it widened by 133.5 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 2 analysts of 33.8% for the fiscal year ending Dec 2026, up from 33.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
19.0%+6.8 pp QoQ
Last fiscal yearDec 2025
33.2%+13.3 pp YoY
LTMMar 2026
31.0%+5.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-7.7 pp——
1 year+13.3 pp+0.6 pp-12.7 pp
3 years+133.5 pp+3.0 pp-130.5 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
33.2%
Year-over-year change
+13.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How XLY.TO compares with its peers on the latest reported figures

  • XLY.TO's LTM Mar 2026 EBITDA Margin of 31.0% is the 2nd highest of the 3 companies compared; the peer median is 20.0%.
  • Its year-over-year change of +5.0 pp is the 2nd highest of 3, against a peer median of +3.8 pp.
  • Over three fiscal years its change of +133.5 pp compares with a peer median of +5.5 pp.
XLY.TO Competitors Peer median
EBITDA Margin for XLY.TO and competitors
Company Period LTM level YoY 3-year change
HLS.TOHLS Therapeutics Inc.LTM Mar 202631.9% +6.2 pp+2.6 pp
XLY.TOAuxly Cannabis Group Inc.LTM Mar 202631.0% +5.0 pp+133.5 pp
CRRX.TOCareRx CorporationLTM Mar 20268.0% +1.5 pp+8.3 pp
CRDL.TOCardiol Therapeutics Inc.FY2025— ——
Peer median (excluding XLY.TO) 20.0%+3.8 pp+5.5 pp

Competitors are the stored peer set for XLY.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue83.83M94.47M101.08M122.33M151.48M
Cost of Revenue64.54M77.96M79.8M62.4M64.74M
Gross Profit19.29M16.51M21.28M59.93M86.74M
Gross Margin23.0%17.5%21.1%49.0%57.3%
Research & Development298K292K497K00
Selling, General & Admin45.42M50.38M40.28M40.73M49.07M
Operating Expenses58.23M65.49M47.23M45.22M54.07M
Depreciation & Amortization14.27M20.18M11.21M10.28M11.45M
EBITDA(18.3M)(94.79M)(10.89M)24.38M50.31M
EBITDA Margin-21.8%-100.3%-10.8%19.9%33.2%
Operating Income(38.94M)(48.98M)(25.95M)14.71M32.67M
Operating Margin-46.4%-51.8%-25.7%12.0%21.6%
Interest Income1.59M337K32K240K130K
Interest Expense17.67M21.58M25.65M14.46M6.34M
Other Income / Expenses(11.3M)(87.58M)(21.8M)(15.07M)(155K)
Income Before Tax(50.24M)(136.56M)(47.75M)(356K)32.52M
Pre-Tax Margin-59.9%-144.5%-47.2%-0.3%21.5%
Income Tax Expense(4.33M)(6.26M)(3.24M)15.99M(9.34M)
Net Income(33.74M)(130.29M)(44.51M)(16.35M)41.86M
Net Margin-40.2%-137.9%-44.0%-13.4%27.6%
EPS (Basic)(0.06)(0.15)(0.04)(0.01)0.03
EPS (Diluted)(0.06)(0.15)(0.04)(0.01)0.03
Weighted Avg Shares783.38M889.87M990.99M1.2B1.33B
Weighted Avg Shares (Diluted)783.38M889.87M990.99M1.2B1.59B

Auxly Cannabis Group Inc.

TSX:XLY.TO

Intrinsic Alpha fair value

Locked

Current Price

$3.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.